June 2 (Reuters) - Travere Therapeutics said on Tuesday it has signed a licensing pact with privately held biotech Everest ...

Travere Therapeutics (TVTX) stock is in focus as the company inks a licensing deal worth up to $1.1B with China’s Everest ...

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines for the development and commercialization ...

The licensing deal, announced Tuesday with China’s Everest Medicines, gives Travere exclusive rights to develop and sell the ...

Travere Therapeutics has set its sights on Everest Medicines' therapy for rare kidney diseases, paying $112.5 million upfront for a drug that has already begun the trek into the clinic. The deal, ...

VRTX moves closer to a potential nephrology launch as the FDA accepts its BLA for povetacicept in adults with IgAN, with a decision due in November 2026.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Travere Therapeutics (TVTX) and Glaukos (GKOS) with bullish sentiments. According to TipRanks.com, Rama ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced its intention to offer, subject to market and other conditions, $400 million aggregate principal amount of convertible senior notes due 2032 ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the “Notes”) ...